Active, not recruitingPhase 1NCT03860272
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Studying Angiosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Agenus Inc.
- Principal Investigator
- Medical DirectorAgenus Inc.
- Intervention
- Botensilimab(drug)
- Enrollment
- 499 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2027
Study locations (18)
- HonorHealth Research Institute, Scottsdale, Arizona, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- The Angeles Clinic & Research Institute, a Cedars-Sinai Affiliate, Los Angeles, California, United States
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UCLA Santa Monica Hematology Oncology, Los Angeles, California, United States
- Saint John's Cancer Institute, Santa Monica, California, United States
- University of Colorado, Aurora, Colorado, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Columbia University Medical Center, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Providence Portland Cancer Center, Portland, Oregon, United States
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03860272 on ClinicalTrials.govOther trials for Angiosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06898970Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaVarun Monga, MBBS
- RECRUITINGPHASE2NCT07007273Pembrolizumab for Advanced Cutaneous Sarcomas Not Including AngiosarcomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06715579Cardiac Angiosarcoma International RegistryImmune Oncology Research Institute
- RECRUITINGPHASE2NCT06849986IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)Fudan University
- RECRUITINGPHASE2NCT06673628Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsNational Cancer Center, Japan
- RECRUITINGPHASE1NCT06440005A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsAngiex, Inc.
- RECRUITINGNCT06375941Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStarsItalian Sarcoma Group
- RECRUITINGNCT06541652A French Multicenter Observational Retrospective Study of Rare Primary Liver CancersFederation Francophone de Cancerologie Digestive